WAY's AI-driven RCM growth and strong Q1 results stand out, while TruBridge trades near its pending buyout price with limited upside.
Investors looking for stocks in the Medical Info Systems sector might want to consider either TruBridge (TBRG) or Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
TruBridge climbs after Q1 EPS beats estimates and an IKS Health buyout deal sets a $26.25-per-share cash offer for shareholders.
Investors interested in Medical Info Systems stocks are likely familiar with TruBridge (TBRG) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
TruBridge (TBRG) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.36 per share a year ago.
TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TruBridge (TBRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
TruBridge (TBRG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TruBridge, Inc. (TBRG) Q4 2025 Earnings Call Transcript
TruBridge (TBRG) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.05 per share a year ago.
TruBridge (TBRG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.